The Indian Journal of Pediatrics

, Volume 68, Issue 8, pp 733–736 | Cite as

Typhoid vaccines

Special Article


Typhoid fever continues to be a major public health problem in developing countries with about 33 million cases per year. Protective efficacy of traditional acetone/phenol killed vaccines is similar to newer typhoid vaccines (Ty21A and Vi antigen vaccine) but side effects of these newer vaccines are considerably less. Though the mortality is low, typhoid fever causes considerable morbidity and loss of working days. Problems during treatment are increasing due to emergence and spread of multidrug resistant S. typhi. Hence to decrease the incidence of typhoid fever in addition to ensuring safe water supply and excreta disposal a typhoid vaccine needs to be introduced in the National Immunization Schedule.

Key words

Typhoid vaccine Typhoid fever 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ivanoff B, Levine MM. Typhoid fever. Continuing challenges from a resilient bacterial foe. Bull lnst Pasteur 1997;95:129–142.CrossRefGoogle Scholar
  2. 2.
    Committee on issues and priorities for new vaccine development. The burden of disease resulting from various diarrhoeal pathogens. In New Vaccine Developntent Establishing Priorities. Vol. 2. Diseases of importance in developing countries. Washington DC, National Academy Press, 1986.Google Scholar
  3. 3.
    Edelman R, Levine MM. Summary of an International workshop on typhoid fever. Rev Infect Dis 1986;8:329–349.PubMedGoogle Scholar
  4. 4.
    Middlekemp JN. Typhoid fever in infants and children. Med Times 1965;93:956–962.Google Scholar
  5. 5.
    Ferreccio C, Levine MM, Manterola A et al. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatr 1984;104:899–901.CrossRefPubMedGoogle Scholar
  6. 6.
    Klugman KP, Gilbertson IT, Koornhof HJ et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987;21:1165–1169.CrossRefGoogle Scholar
  7. 7.
    Sinha A, Sazawal S, Kumar R et al. Typhoid fever in children less than 5 years. Lancet 1999;354:734–737.CrossRefPubMedGoogle Scholar
  8. 8.
    Levine MM. Typhoid fever vaccines. In Orenstein WA, ed. Plotkin Sa Vaccines. 3rd edn. W. B Saunders Company London 1999;781–814.Google Scholar
  9. 9.
    Anand AC, Kataria VK, Singh W. Epidemic multidrug resistant enteric fever in eastern India (letter). Lancet 1990;335:352.CrossRefPubMedGoogle Scholar
  10. 10.
    Bhutta ZA, Naqvi SH, Razzaq, Farooqui BJ. Multidrug resistant typhoid in children. Presentation and clinical features. Rev Infect Dis 1991;13:832–836.PubMedGoogle Scholar
  11. 11.
    Gupta A. Multidrug resistant typhoid fever in children. Epidemiology and therapeutic approach. Pediatr Infect Dis 1994;13:124–140.Google Scholar
  12. 12.
    Mikhail IA, Haberberger RL, Farid Z. Antibiotic multidrug resistant Salmonella Typhi in Eygpt. Tran R Soc Trop Med Hyg 1984;83:120.CrossRefGoogle Scholar
  13. 13.
    Acharaya IL, Lowe CU, Thapa R et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi:A preliminary report. N Eng J Med 1987;3179:1101–1104.CrossRefGoogle Scholar
  14. 14.
    Ryan CA, Hargrett-Bean NT, Blake PA. Salmonella typhi infection in the United States,1975–1984. Increasing role of foreign travel. Rev Infect Dis 1989;2:1–8.Google Scholar
  15. 15.
    Beaser MJ, Lofgren JP. Fatal Salmonellosis originating in a clinical microbiology laboratory. J Clin Microbiol 1981;13:855–858.Google Scholar
  16. 16.
    Kumar H. Typhoid vaccine. In Mittal SK, Datta AK, Aggarwal V, eds. Update Immunization. CBS Publishers, New Delhi 1994;73–88.Google Scholar
  17. 17.
    Gupta A, Jalla S, Sazawal S, Bhan MK. Advances in Vaccines for typhoid fever. Indian J Pediatr 1998;65:545–63.Google Scholar
  18. 18.
    Asherof MT, Singh B, Nicholson CC et al. A seven year field trial of two typhoid vaccines in Guiana. Lancet 1967;2:1056–1059.Google Scholar
  19. 19.
    Hejfec LB, Salmin LV, Lejtiman MZ. A controlled field trial and laboratory study of five typhoid vaccines in USSR. Bull WHO 1966;34:321–339.PubMedGoogle Scholar
  20. 20.
    Tapas, Cvjetannovic B. Controlled field trial on the effectiveness of one or two doses of acetone inactivated and dried typhoid vaccine, Bull WHO 1975;52:75–80.Google Scholar
  21. 21.
    Wong KH, Feeley JC, Pittman M. Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol. J Infect Dis 1974;129:501–506.PubMedGoogle Scholar
  22. 22.
    American Academy of Pediatrics. Salmonella infections. In 2000 Red Book:report of Committee of infectious Disease, 25th edn. Elk Grove Village IL: American Academy of Pediatrics 2000:501–506Google Scholar
  23. 23.
    Germanier R, Furer E. Isolation and characterization of gal E mutant ty21a Salmonella typhi. A candidate strain for live oral vaccine. J Infect Dis 1975;141:553–558.Google Scholar
  24. 24.
    Wahdan MH, Szie C, Cerisier Y, Germanier R. A controlled trial of live Salmonella typhi strain ty21a oral vaccine against typhoid. Three year results. J Infect Dis 1982;145:292–296.PubMedGoogle Scholar
  25. 25.
    Levine MM, Ferreccio C, Black RE, Germanier R. Children typhoid Committee. Large scale field trials of Ty21a. Live oral vaccine in enteric coated capsule formulation. Lancet 1987;1:1049–1052.CrossRefPubMedGoogle Scholar
  26. 26.
    Levine MM, Ferrecio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989;2:552–567.Google Scholar
  27. 27.
    Mirz NB, Wamola IA, Estambale BA, Mbhiti E, Poillet M. Typhi in Vi vaccine against typhoid fever. A clinical trial in Kenya. East African Med J 1995;72(3):162–164.Google Scholar
  28. 28.
    Szu SC, Stone AC, Robbins JP. Preparation and characterization of conjugates of the Vi capsular polysaccharide and carrier proteins. J Exp Med 1987;167:1510–1524.CrossRefGoogle Scholar
  29. 29.
    Hackett J. Salmonella based vaccines. Vaccine 1990;8:5–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Levine MM, Herrington D, Murphy IR et al. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541 Ty and 543 Ty as live oral vaccines in a man. J Clin Invest 1987;79:888–902.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2001

Authors and Affiliations

  1. 1.Lady Hardinge Medical College and Kalawati Saran Children's HospitalESI HospitalNew Delhi

Personalised recommendations